1. University of Kansas, USA

Abstract

The SLC22 family of transporters is mostly composed of non-selective transporters, which are expressed highly in liver, kidney and intestine, playing a major role in drug disposition. The family may be divided into three subfamilies based on the nature of the substrate transported: organic cations (OCTs), organic anions (OATs) and organic zwiterrion/cations (OCTN). Membrane topology is predicted to contain 12 TM domains with intracellular termini, and an extended extracellular loop at TM 1/2.

Contents

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [3].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

References

1. Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ and Sharman JL et al.. (2019) THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters. Br J Pharmacol 176 Suppl 1: S397-S493 [PMID:31710713]
2. Bajjalieh SM, Peterson K, Linial M and Scheller RH. (1993) Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci USA 90: 2150-4 [PMID:7681585]
3. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it Database 2020 [PMID:32367113]
4. Burns CM and Wortmann RL. (2011) Gout therapeutics: new drugs for an old disease. Lancet 377: 165-77 [PMID:20719377]
5. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y and Endou H. (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275: 4507-12 [PMID:10660625]
6. Diaz-Torné C, Perez-Herrero N and Perez-Ruiz F. (2015) New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 27: 164-9 [PMID:25603039]
7. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T and Igarashi T et al.. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-52 [PMID:12024214]
8. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A and Selgas R et al.. (2011) Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011: 354908 [PMID:21716719]
9. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE and Koepsell H. (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16: 871-81 [PMID:9260930]
10. Gründemann D, Liebich G, Kiefer N, Köster S and Schömig E. (1999) Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 56: 1-10 [PMID:10385678]
11. Gründemann D, Schechinger B, Rappold GA and Schömig E. (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1: 349-51 [PMID:10196521]
12. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, Sugihara S, Igawa O, Hosoya T and Ohtahara A et al.. (2008) Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21: 1157-62 [PMID:18670416]
13. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T and Endou H. (2003) Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63: 143-55 [PMID:12472777]
14. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV and Gillard MR et al.. (2004) Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 47: 530-49 [PMID:14736235]
15. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K and Endou H. (2002) Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther 301: 293-8 [PMID:11907186]
16. Klitgaard H and Verdru P. (2007) Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov 2: 1537-45 [PMID:23484603]
17. Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34: 413-35 [PMID:23506881]
18. Kuang W, Zhang J, Lan Z, Deepak RNVK, Liu C, Ma Z, Cheng L, Zhao X, Meng X and Wang W et al.. (2021) SLC22A14 is a mitochondrial riboflavin transporter required for sperm oxidative phosphorylation and male fertility. Cell Rep 35: 109025 [PMID:33882315]
19. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y and Endou H. (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274: 13675-80 [PMID:10224140]
20. Longo N, Frigeni M and Pasquali M. (2016) Carnitine transport and fatty acid oxidation. Biochim Biophys Acta 1863: 2422-35 [PMID:26828774]
21. Löscher W, Gillard M, Sands ZA, Kaminski RM and Klitgaard H. (2016) Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. CNS Drugs 30: 1055-1077 [PMID:27752944]
22. Madeo M, Kovács AD and Pearce DA. (2014) The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. J Biol Chem 289: 33066-71 [PMID:25326386]
23. Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfán BV, Carmona-Aparicio L and Gómez-Lira G. (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci 38: 3529-39 [PMID:24102679]
24. Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L and Matagne A et al.. (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57: 201-9 [PMID:26663401]
25. Nigam SK and Bhatnagar V. (2018) The systems biology of uric acid transporters: the role of remote sensing and signaling. Curr Opin Nephrol Hypertens 27: 305-313 [PMID:29847376]
26. Noyer M, Gillard M, Matagne A, Hénichart JP and Wülfert E. (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286: 137-46 [PMID:8605950]
27. Pao SS, Paulsen IT and Saier Jr MH. (1998) Major facilitator superfamily. Microbiol Mol Biol Rev 62: 1-34 [PMID:9529885]
28. Perland E, Bagchi S, Klaesson A and Fredriksson R. (2017) Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression. Open Biol 7 [PMID:28878041]
29. Perland E and Fredriksson R. (2017) Classification Systems of Secondary Active Transporters. Trends Pharmacol Sci 38: 305-315 [PMID:27939446]
30. Reddy VS, Shlykov MA, Castillo R, Sun EI and Saier Jr MH. (2012) The major facilitator superfamily (MFS) revisited. FEBS J 279: 2022-35 [PMID:22458847]
31. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC and Burchard EG et al.. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117: 1422-31 [PMID:17476361]
32. Takeda M, Babu E, Narikawa S and Endou H. (2002) Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438: 137-42 [PMID:11909604]
33. Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M and Iwanaga T. (2019) Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. J Pharmacol Exp Ther 371: 162-170 [PMID:31371478]
34. Vogl C, Tanifuji S, Danis B, Daniels V, Foerch P, Wolff C, Whalley BJ, Mochida S and Stephens GJ. (2015) Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses. Eur J Neurosci 41: 398-409 [PMID:25484265]
35. von Rosenstiel P. (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4: 84-7 [PMID:17199019]
36. Yee SW, Buitrago D, Stecula A, Ngo HX, Chien HC, Zou L, Koleske ML and Giacomini KM. (2020) Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. FASEB J 34: 15734-15752 [PMID:33124720]
37. Yee SW, Stecula A, Chien HC, Zou L, Feofanova EV, van Borselen M, Cheung KWK, Yousri NA, Suhre K and Kinchen JM et al.. (2019) Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. PLoS Genet 15: e1008208 [PMID:31553721]
38. Youngblood GL and Sweet DH. (2004) Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol 287: F236-44 [PMID:15068970]
39. Yu Z, Fong WP and Cheng CH. (2007) Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metab Dispos 35: 981-6 [PMID:17325024]
40. Zhang L, Schaner ME and Giacomini KM. (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286: 354-61 [PMID:9655880]
41. Zhu HJ, Appel DI, Gründemann D and Markowitz JS. (2010) Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem 114: 142-9 [PMID:20402963]